Group 1: Financial Performance - In 2024, the company achieved a revenue of 641 million CNY, representing a growth of 10.23% compared to the previous year [4] - The net profit attributable to shareholders was 91.83 million CNY, an increase of 7.24% year-on-year [4] - R&D expenses for 2024 amounted to 23.98 million CNY, accounting for 3.74% of total revenue [3] Group 2: Product Development and Innovation - The company launched new products including "民生普瑞宝益生菌冻干粉" and "民生普瑞宝即食益生菌" [2] - In 2024, the company added 1 new drug approval, 3 invention patents, and 4 utility model patents [3] - The company is developing a new series of composite nutrient supplements, currently at various stages of R&D [6] Group 3: Market Strategy and Sales - The company reported a 23.69% revenue growth in the Central China region, attributed to targeted market strategies [5] - The vitamin and mineral supplement series saw a revenue increase of 10.47% in 2024 [6] - The company is expanding its e-commerce presence on platforms like Tmall, JD.com, and Douyin [7] Group 4: Strategic Partnerships and Collaborations - The strategic partnership with 中科嘉亿 aims to enhance the company's capabilities in the probiotics sector [4] - The company is leveraging its collaboration to expand its product offerings and market reach in the probiotics field [4] Group 5: Future Outlook and Plans - The company plans to cultivate multiple star products as part of its 2025 operational strategy [5] - Future initiatives include enhancing digital transformation and smart manufacturing to improve efficiency [3] - The company aims to explore international markets and introduce its products globally [6]

证券代码：301507 证券简称：民生健康 公告编号：2025-027 的公告 杭州民生健康药业股份有限公司 关于参加 2025 年浙江辖区上市公司投资者 网上集体接待日暨 2024 年度业绩说明会 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2025 年 5 月 13 日（周二）15:00-17:00。届时公司高 管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、股权激励和 可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊 跃参与！ 特此公告。 杭州民生健康药业股份有限公司董事会 2025年5月9日 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）《2024 年年度报告》及 其摘要等相关文件已于 2025 年 4 月 25 日在巨潮资讯网（www.cninfo.com.cn）披 露。为进一步加强与投资者的互动交流，公司将参加由 ...

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

Core Insights - Minsheng Health reported a revenue of 641 million yuan for 2024, representing a year-on-year growth of 10.23% [1] - The company achieved a net profit attributable to shareholders of 91.83 million yuan, up 7.24% year-on-year [1] - Basic earnings per share stood at 0.26 yuan [1] Financial Performance - Gross margin for 2024 was 55.77%, a decrease of 6.30 percentage points year-on-year [3] - Net profit margin was 14.32%, a slight decline of 0.40 percentage points year-on-year [3] - Sales expenses amounted to 191 million yuan, an increase of 0.32% year-on-year, primarily for channel maintenance and brand promotion [3] - Research and development expenses were 23.98 million yuan, down 18.87% year-on-year, accounting for 3.74% of revenue [3] Cash Flow Analysis - Net cash flow from operating activities was 108 million yuan, a slight increase of 0.28% year-on-year, indicating stable operating cash collection ability [3] - Net cash outflow from investing activities was 280 million yuan, an increase of 45.53% year-on-year, mainly for fundraising projects and financial product purchases [3] - Net cash flow from financing activities was -38.34 million yuan, a decline of 104% year-on-year [3] Business Segmentation - Revenue from vitamins and minerals reached 621 million yuan, growing 10.47% year-on-year, accounting for 96.91% of total revenue [3] - Revenue from other health products was 12 million yuan, up 8.01% year-on-year, representing 1.93% of total revenue [3] - Probiotic revenue was 4.22 million yuan, down 33.74% year-on-year, making up 0.66% of total revenue [3] Research and Development - The company obtained 3 new authorized invention patents and completed the development of 5 functional food products in 2024 [3] - Ongoing research pipelines include Minoxidil lotion (for hair growth) and traditional Chinese medicine products, with future plans to expand into sleep health and sports nutrition sectors [3]

证券代码：301507 证券简称：民生健康 公告编号：2025-026 杭州民生健康药业股份有限公司 截至 2025 年 4 月 30 日，公司通过回购专用证券账户，以集中竞价交易方 式已累计回购股份 292,500 股，占公司当前总股本的 0.08%，最高成交价为 12.08 元/股，最低成交价为 11.83 元/股，支付金额为 3,503,018 元（不含交易费 用）。 重要内容提示： 回购方案的实施情况：截至 2025 年 4 月 30 日，杭州民生健康药业股份 有限公司（以下简称"公司"）通过回购专用证券账户，以集中竞价交易方式已 累计回购股份 292,500 股，占公司当前总股本的 0.08%，最高成交价为 12.08 元 /股，最低成交价为 11.83 元/股，支付金额为 3,503,018 元（不含交易费用）。 一、 回购股份的基本情况 公司于 2025 年 3 月 19 日召开第二届董事会第七次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司通过集中竞价交易方式以自 有资金回购部分社会公众股份，用于股权激励。回购价格不超过人民币 19.80 元 /股；预计回购股份数量为 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-025 杭州民生健康药业股份有限公司 关于举办 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）《2024 年年度报告》及 其摘要等相关文件已于 2025 年 4 月 25 日在巨潮资讯网（www.cninfo.com.cn）披 露。为便于广大投资者进一步了解公司的财务状况、经营情况及公司发展规划， 公司定于 2025 年 5 月 14 日（周三）15:00-16:30 在全景网举办 2024 年度网上业 绩说明会，本次业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投 资者关系互动平台"（https://ir.p5w.net）参与本次业绩说明会或者直接进入公司路 演厅（https://ir.p5w.net/c/301507.shtml）参与本次业绩说明会。 出席本次业绩说明会的人员有：公司董事长竺福江先生、总经理张海军先生、 财务负责人朱文君先生、独立董事刘玉龙先生、董事会秘书陈稳竹先生。（如有 特 ...

Financial Performance - The financial officer provided a detailed overview of the company's financial status for the full year 2024 and the first quarter of 2025, covering overall financial data, revenue composition, R&D investment, and operational capability indicators [1] - The company's gross profit margin fluctuated significantly on a quarterly basis, primarily influenced by the "opening red" effect in Q1, with expectations for stabilization as new products are launched [4] Market Overview and Strategic Planning - The general manager discussed the main market conditions over the past year and the business plans for the upcoming year, emphasizing the stability of the vitamin and mineral segment and the establishment of new product lines [1][2] - The company aims for diversified revenue sources through a richer product matrix and continuous optimization of the sales channel system [3] Product Development and Sales Channels - The company has established independent business units for new product development and operations, including the Medical Aesthetics Division and International Business Division, with two recently approved products expected to launch in Q3 [2] - The online sales share has seen significant growth, with future targets set for a reasonable proportion of online sales within the overall strategy [3] Cost and Taxation Considerations - The impact of tariffs on the company's operations is minimal, as the majority of business is focused on the domestic market, with only a small portion of imported reagents [5] - The sales performance of offline pharmacies has stabilized after initial policy and market environment impacts, with expectations for limited overall influence on the company [5] International Expansion Plans - The company plans to promote existing high-quality product categories to international markets, aiming to meet similar nutritional needs of overseas consumers [5] - There is also an intention to introduce mature foreign formulations to enhance product offerings through the company's brand and channel advantages [5] Meeting Summary - The board secretary concluded the online performance exchange meeting, expressing gratitude to the organizers and participating investment institutions [6]

Core Insights - Minsheng Health reported a revenue of 641 million yuan for 2024, marking a year-on-year growth of 10.23%, with a net profit of 91.83 million yuan, up 7.24% [1] - The company continues to show strong growth in Q1 2025, achieving a revenue of 271 million yuan, a 15.70% increase year-on-year [1] - The brand "21 Jin Weita" has solidified its position as a leading name in the mineral and vitamin sector, with product revenue surpassing 600 million yuan for the first time in 2024 [1][4] Financial Performance - For 2024, the company achieved a net cash flow from operating activities of 108 million yuan [1] - The first quarter of 2025 saw a net profit of 62.71 million yuan, reflecting a 6.51% increase compared to the same period last year [1] Research and Development - In 2024, the company invested 23.98 million yuan in R&D, accounting for 3.74% of its revenue [2] - The company and its subsidiaries obtained 1 new drug approval, 3 invention patents, and 4 utility model patents during the reporting period [2][5] Market Strategy - Minsheng Health is expanding its product matrix in the health sector, focusing on treatment OTC drugs and probiotics, in line with the "New Products, New Business, New Models, New Projects" strategy [3] - The company aims to enhance its core competitiveness in the health sector by exploring new areas such as gastrointestinal health, medical aesthetics, and smoking cessation [2][3] Brand Development - The brand "21 Jin Weita" has gained recognition, ranking among the top three brands in the Chinese market for multivitamins in 2024 [4] - The company is reviving the "Minsheng Tongchun" brand, which dates back to 1926, to cater to modern health needs [4] Industry Trends - The health product market in China is expected to grow significantly, with current consumption levels of dietary supplements being only one-fifth of those in developed countries [3] - The probiotics market is projected to grow at an annual rate of 11-12%, potentially reaching a market size of 137.7 billion yuan by 2026 [7] Strategic Partnerships - Minsheng Health signed a strategic cooperation agreement with Zhongke Jiayi to enhance its capabilities in the probiotics sector [7][8] - The partnership aims to develop a comprehensive probiotics platform, enhancing the company's market position and technical capabilities [8] Product Innovation - The company launched a new product "Jisuran" targeting the skin repair market, utilizing peptide technology [9] - A new liquid formulation of aluminum magnesium carbonate has been developed to meet the needs of younger consumers [9][10] Future Outlook - The company anticipates that the introduction of new products and business lines will lead to substantial growth in its operations [11]

Core Viewpoint - The company is experiencing growth in the health supplement market, driven by increasing health awareness and consumer demand for preventive healthcare products, leading to a strategic focus on product innovation and market expansion [3][5][19]. Company Overview - The company operates in the pharmaceutical manufacturing industry, specifically in the OTC (over-the-counter) drug and health supplement sectors, with its main product being the 21 Jinweita Multivitamin [3][4]. - The health supplement market in China is expanding, with significant growth potential compared to developed countries, as consumer awareness and demand for dietary supplements increase [4][7]. Industry Trends - The non-prescription drug market is benefiting from a shift towards preventive healthcare, supported by national policies promoting health awareness and consumer education [5][6]. - The aging population in China is driving demand for health management products, with a notable increase in the elderly demographic, which is expected to further boost the health supplement market [8][9]. Business Performance - The company reported a revenue of 641 million yuan, a year-on-year increase of 10.23%, and a net profit of 91.83 million yuan, up 7.24% from the previous year [19]. - The company is focusing on expanding its product matrix in the health supplement sector, enhancing its brand presence, and optimizing its sales channels to improve market competitiveness [10][14]. Product and Brand Strategy - The company has a diverse product range, primarily focusing on vitamins and minerals, and is committed to continuous research and development to meet varying consumer needs [11][12]. - The brand "21 Jinweita" has established itself as a leading name in the vitamin and mineral sector, with recognition in various industry awards and rankings [13]. Marketing and Sales Network - The company has developed a comprehensive marketing network, utilizing both online and offline channels to reach consumers effectively, including major e-commerce platforms [14]. - The company is adapting its sales strategies to align with changing consumer behaviors and preferences, ensuring broad market coverage [14]. Management and Innovation - The company boasts a professional management team with extensive experience in the health product sector, focusing on innovation and compliance with industry standards [15]. - The company has established a robust core technology system for product formulation and quality control, continuously improving its capabilities [16].

Group 1 - Shenjian Co., Ltd. reported a net profit of 33.65 million yuan for 2024, a year-on-year increase of 32.29%, with a proposed cash dividend of 0.5 yuan per 10 shares [1] - Jingce Electronics experienced a net loss of 97.60 million yuan in 2024, transitioning from profit to loss, despite a revenue increase of 5.59% to 2.565 billion yuan [1] - Jingwei Co., Ltd. reported a net profit of 35.54 million yuan for 2024, a decrease of 36.76%, with a proposed cash dividend of 1.00 yuan per 10 shares [1][2] Group 2 - Minsheng Health achieved a net profit of 91.83 million yuan in 2024, a year-on-year increase of 7.24%, with a proposed cash dividend of 1.00 yuan per 10 shares [2] - Zhongshe Co., Ltd. reported a net profit of 10.16 million yuan for 2024, a decline of 76.24%, with a proposed cash dividend of 0.2 yuan per 10 shares [3] - Keyuan Smart reported a net profit of 252 million yuan for 2024, a year-on-year increase of 56.64%, with a proposed cash dividend of 0.4 yuan per 10 shares [4] Group 3 - Beilu Pharmaceutical reported a net profit of 14.54 million yuan for Q1 2025, a year-on-year increase of 26.13%, with revenue of 283 million yuan [5] - Wangsu Technology achieved a net profit of 192 million yuan for Q1 2025, a year-on-year increase of 38.54%, with revenue of 1.235 billion yuan [6] - Keyuan Pharmaceutical reported a net profit of 23.08 million yuan for Q1 2025, a year-on-year increase of 7.25%, despite a revenue decline of 23.98% [7] Group 4 - Guangting Information reported a net profit of 24.03 million yuan for Q1 2025, turning from loss to profit, with revenue of 134 million yuan [9] - Zhaori Technology reported a net loss of 1.23 million yuan for Q1 2025, with revenue of 35.23 million yuan [11] - Huakai Yibai reported a net loss of 15.09 million yuan for Q1 2025, despite revenue growth of 35.08% to 2.292 billion yuan [13] Group 5 - Xinhongye reported a net profit of 34.43 million yuan for Q1 2025, a year-on-year increase of 20.43%, with revenue of 755 million yuan [15] - Huning Co., Ltd. reported a net profit of 3.61 million yuan for Q1 2025, a year-on-year decrease of 45.68%, with revenue of 64.51 million yuan [16] - Camel Co., Ltd. reported a net profit of 237 million yuan for Q1 2025, a year-on-year increase of 51.89%, with revenue of 4.136 billion yuan [17] Group 6 - Hengtong Co., Ltd. reported a net profit of 42.55 million yuan for Q1 2025, a year-on-year increase of 51.62%, with revenue of 313 million yuan [19] - Changqing Technology reported a net profit of 35.38 million yuan for Q1 2025, a year-on-year decrease of 23.80%, with revenue of 246 million yuan [21] - Libaba Co., Ltd. reported a net profit of 34.72 million yuan for Q1 2025, a year-on-year increase of 9.91%, with revenue of 419 million yuan [22] Group 7 - Shouxiangu reported a net profit of 58.37 million yuan for Q1 2025, a year-on-year decrease of 24.32%, with revenue of 171 million yuan [24] - Bojun Technology announced a stock issuance application accepted by the Shenzhen Stock Exchange [24] - Dayou Energy announced the full resumption of production at its Gengcun coal mine, with an annual production capacity of 3.6 million tons [25] Group 8 - Deyang Co., Ltd. successfully acquired land use rights for industrial land in Ningbo for 45.80 million yuan [27] - Tianyu Pharmaceutical's subsidiary received a drug registration certificate for an injectable product [29] - Xingwang Yuda signed a strategic cooperation agreement with the Jilin Province Bionic Robot Innovation Center [30] Group 9 - Lifang Pharmaceutical received approval for clinical trials of a new drug [32] - Zai Sheng Technology reported a net profit of 33.56 million yuan for Q1 2025, a year-on-year increase of 3.69%, with revenue of 324 million yuan [34] - Jinxin Technology reported a net profit of 319,920 yuan for Q1 2025, turning from loss to profit, with revenue of 563 million yuan [36] Group 10 - Huayin Electric reported a net profit of 75.67 million yuan for Q1 2025, a year-on-year increase of 894.61%, with revenue of 2.307 billion yuan [37] - Xinghua Co., Ltd. reported a net loss of 95.51 million yuan for Q1 2025, with revenue of 840 million yuan [38] - Heren Technology reported a net loss of 384,410 yuan for Q1 2025, with revenue of 78.40 million yuan [40] Group 11 - Fenda Technology reported a net profit of 40.45 million yuan for Q1 2025, a year-on-year increase of 84.07%, with revenue of 760 million yuan [41] - Tongda Co., Ltd. reported a net profit of 25.49 million yuan for 2024, a year-on-year decrease of 69.15%, with revenue of 6.201 billion yuan [43] - Zhonghe Holdings reported a net profit of 283 million yuan for 2024, a year-on-year decrease of 54.69%, with a proposed cash dividend of 0.3 yuan per 10 shares [44] Group 12 - Jiantou Energy reported a net profit of 531 million yuan for 2024, a year-on-year increase of 181.59%, with a proposed cash dividend of 1.3 yuan per 10 shares [44] - Guanghua Technology reported a net loss of 205 million yuan for 2024, with revenue of 2.589 billion yuan [45] - Huajin Technology reported a net profit of 29.26 billion yuan for 2024, a year-on-year increase of 8.1%, with a proposed cash dividend of 9 yuan per 10 shares [46] Group 13 - Yingke Medical reported a net profit of 1.465 billion yuan for 2024, a year-on-year increase of 282.63%, with a proposed cash dividend of 1.00 yuan per 10 shares [46] - Solar Energy reported a net profit of 1.225 billion yuan for 2024, a year-on-year decrease of 22.38%, with a proposed cash dividend of 0.56 yuan per 10 shares [46] - Dongfang Electric reported a net profit of 318 million yuan for 2024, a year-on-year decrease of 50.62%, with a proposed cash dividend of 0.32 yuan per 10 shares [47] Group 14 - Tianneng Heavy Industry reported a net loss of 262 million yuan for 2024, with revenue of 3.273 billion yuan [48] - Gangyan High-tech reported a net profit of 249 million yuan for 2024, a year-on-year decrease of 22.08%, with a proposed cash dividend of 1.00 yuan per 10 shares [48] - Shihua Machinery reported a net profit of 96.88 million yuan for 2024, a year-on-year increase of 5.35%, with revenue of 8.037 billion yuan [49] Group 15 - Gongtong Pharmaceutical reported a net loss of 27.59 million yuan for 2024, with revenue of 537 million yuan [51] - Zhongjing Electronics reported a net loss of 87.43 million yuan for 2024, with revenue of 2.932 billion yuan [53] - Yudai Development reported a net loss of 114 million yuan for 2024, with revenue of 388 million yuan [55] Group 16 - Zhenhua Technology reported a net profit of 970 million yuan for 2024, a year-on-year decrease of 63.83%, with a proposed cash dividend of 1.8 yuan per 10 shares [56] - Jierong Technology reported a net loss of 298 million yuan for 2024, with revenue of 1.357 billion yuan [58] - Changgao Electric New reported a net profit of 252 million yuan for 2024, a year-on-year increase of 45.66%, with a proposed cash dividend of 0.8 yuan per 10 shares [60] Group 17 - Shibao Detection announced a plan to acquire 81% of Zhonghuan Lianshu for 52.65 million yuan [61] - Jiangsu Boyun announced a plan to reduce its shareholding by up to 3% [62] - Jingfeng Mingyuan announced a plan to acquire 100% of Yichong Technology for 3.283 billion yuan [63]